Evidence map›Paper›PMID 27942891›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2017

Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival.

M de Ridder, Z A R Gouw, J J Sonke, A Navran, B Jasperse, J Heukelom, M E T Tesselaar, W M C Klop, M W M van den Brekel, Abrahim Al-Mamgani

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2020
    Article
  3. Adaptive radiotherapy for head and neck cancer.Cancers of the head & neck · 2020
    Review
  4. FDG-PET/CT improves detection of residual disease and reduces the need for examination under anaesthesia in oropharyngeal cancer patients treated with (chemo-)radiation.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

M de RidderDepartment of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Z A R GouwDepartment of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
J J SonkeDepartment of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
A NavranDepartment of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
B JasperseDepartment of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
J HeukelomDepartment of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
M E T TesselaarDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
W M C KlopDepartment of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands.
M W M van den BrekelDepartment of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abrahim Al-MamganiDepartment of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. a.almamgani@nki.nl.
The Netherlands Cancer Institute · NLOncode Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objectives is to thoroughly analyze the pattern of failure and oncologic outcome in recurrent oropharyngeal cancer (OPC) after (chemo)radiotherapy and correlate the site of failure to the planned radiation dose. Between January 2010 and April 2014, 57 patients with recurrent OPC after (chemo)radiotherapy were analyzed. Endpoints were pattern of failure and overall survival (OS). Local (LF) and regional failure (RF) were classified as in-field [>50% within gross tumor volume (GTV)], marginal [<50% within GTV but >50% within clinical target volume (CTV)], or out-of-field (>50% outside CTV) recurrences. In the whole group, 70 recurrences were reported. Of the 31 LF, 29 (93.5%) were in-field and 2 (6.5%) were marginal. No out-field LF was reported. Of the 21 RF, 13 RF (62%) were in-field, 6 (28.5%) marginal, and 2 (9.5%) out-of-field recurrences. Forty-three percent of RF was developed in an electively treated neck level, and 2 of them were contralateral. OS at 2 years in recurrent HPV positive, compared to HPV-negative OPC, were 66 and 18%, respectively (p = 0.011). OS was also significantly better in patients that were salvage treatment which was possible (70 vs. 6%, p < 0.001). Median survival after distant failure was 3.6 months. The great majority of LFs were located within the GTV and 43% of RFs developed in an electively treated neck level. The currently used margins and dose recipe and the indication for bilateral nodal irradiation need to be reevaluated. OS was significantly better in recurrent HPV-positive OPC and in patients, where salvage treatment was possible.

Indexed as

AgedAged, 80 and overCarcinoma, Squamous CellFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalOropharyngeal NeoplasmsRadiotherapy DosageRadiotherapy, Intensity-ModulatedSalvage TherapyTreatment Failure(Chemo)radiationHPVPattern of failureRecurrent oropharyngeal cancer

Identifiers

PMID27942891
OpenAlexW2560790944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.